相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Risks of malignancies among patients with psoriasis: A cohort study of 360 patients
Tomoya Watanabe et al.
JOURNAL OF DERMATOLOGY (2023)
Immunogenic cell stress and death
Guido Kroemer et al.
NATURE IMMUNOLOGY (2022)
Immune-checkpoint inhibitors: long-term implications of toxicity
Douglas B. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Machine Learning Applications in Drug Repurposing
Fan Yang et al.
INTERDISCIPLINARY SCIENCES-COMPUTATIONAL LIFE SCIENCES (2022)
Why 90 % of clinical drug development fails and how to improve it?
Duxin Sun et al.
ACTA PHARMACEUTICA SINICA B (2022)
Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
Lin Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
Patricia Iranzo et al.
FRONTIERS IN MEDICINE (2022)
Hybridization Approach to Identify Salicylanilides as Inhibitors of Tubulin Polymerization and Signal Transducers and Activators of Transcription 3 (STAT3)
Marta Gargantilla et al.
PHARMACEUTICALS (2022)
Rafoxanide sensitizes colorectal cancer cells to TRAIL-mediated apoptosis
Federica Laudisi et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
Dobrin Draganov et al.
NPJ BREAST CANCER (2021)
Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction
Elena Fattakhova et al.
CHEMMEDCHEM (2021)
Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β
Jyoti B. Kaushal et al.
CANCERS (2021)
Flubendazole Elicits Antitumor Effects by Inhibiting STAT3 and Activating Autophagy in Non-small Cell Lung Cancer
Xiaona Xie et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Trial watch: intratumoral immunotherapy
Juliette Humeau et al.
ONCOIMMUNOLOGY (2021)
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Filippo Veglia et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Albendazole negatively regulates keratinocyte proliferation
Davide Di Fusco et al.
CLINICAL SCIENCE (2020)
Profiling global cancer incidence and mortality by socioeconomic development
Joannie Lortet-Tieulent et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Morgane Denis et al.
FRONTIERS IN IMMUNOLOGY (2020)
Rafoxanide Induces Immunogenic Death of Colorectal Cancer Cells
Antonio Di Grazia et al.
CANCERS (2020)
Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System
Federica Laudisi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The tumor microenvironment
Nicole M. Anderson et al.
CURRENT BIOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
A benzimidazole inhibitor attenuates sterile inflammation induced in a model of systemic autoinflammation in female mice
Federica Agliano et al.
SCIENTIFIC REPORTS (2020)
Detection of immunogenic cell death and its relevance for cancer therapy
Jitka Fucikova et al.
CELL DEATH & DISEASE (2020)
Turning Cold into Hot: Firing up the Tumor Microenvironment
Qianqian Duan et al.
TRENDS IN CANCER (2020)
The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation
Yue Li et al.
CANCER LETTERS (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy
Shichong Lin et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
Eduardo Jose Barbosa et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2019)
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
Fan Luo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Induction of endoplasmic reticulum stress and inhibition of colon carcinogenesis by the anti-helmintic drug rafoxanide
Federica Laudisi et al.
CANCER LETTERS (2019)
Antiproliferative Aspect of Benzimidazole Derivatives' Activity and Their Impact on NF-κB Expression
Katarzyna Blaszczak-Swiatkiewicz
MOLECULES (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy
Jiangbo Wang et al.
BIOCHEMICAL JOURNAL (2019)
Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor
Qingzhi Jiang et al.
FRONTIERS IN ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-κB signaling in esophageal squamous cell carcinoma
Jiali Tao et al.
ONCOTARGETS AND THERAPY (2019)
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma
Nancy S. Younis et al.
SCIENTIFIC REPORTS (2019)
Web-based drug repurposing tools: a survey
Elizabeth Sam et al.
BRIEFINGS IN BIOINFORMATICS (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress
Jiaqiao Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
Susen Burock et al.
BMC CANCER (2018)
Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
Eunhye Oh et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer
Amer Alasadi et al.
CELL DEATH & DISEASE (2018)
Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
Jenny Rubin et al.
Oncotarget (2018)
Lymph Node Metastases in Colon Cancer Are Polyclonal
Peter J. Ulintz et al.
CLINICAL CANCER RESEARCH (2018)
The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation
Kristin Blom et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Anthelminthic drug niclosamide sensitizes the responsiveness of cervical cancer cells to paclitaxel via oxidative stress-mediated mTOR inhibition
Liping Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress
Yingying Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Levamisole promotes murine bone marrow derived dendritic cell activation and drives Th1 immune response in vitro and in vivo
Yubing Fu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model
Tara Williamson et al.
ONCOTARGET (2016)
Molecular Subtyping of Colorectal Cancer: Time to Explore Both Intertumoral and Intratumoral Heterogeneity to Evaluate Patient Outcome
Eric R. Fearon et al.
GASTROENTEROLOGY (2015)
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Dobrin Draganov et al.
SCIENTIFIC REPORTS (2015)
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol et al.
ONCOIMMUNOLOGY (2015)
Drug repositioning from bench to bedside: Tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer
Peter Nygren et al.
ACTA ONCOLOGICA (2014)
Antihelminthic niclosamide modulates dendritic cells activation and function
Chieh-Shan Wu et al.
CELLULAR IMMUNOLOGY (2014)
Impact of myeloid cells on the efficacy of anticancer chemotherapy
Laura Senovilla et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model
Tinghong Ye et al.
PLOS ONE (2014)
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Labianca et al.
ANNALS OF ONCOLOGY (2013)
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Peter Nygren et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Antihelminth Compound Niclosamide Downregulates Wnt Signaling and Elicits Antitumor Responses in Tumors with Activating APC Mutations
Takuya Osada et al.
CANCER RESEARCH (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells
Sumaiya Sharmeen et al.
BLOOD (2010)
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination
Wenjuan Zhang et al.
VACCINE (2009)
Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells
L. -Y. Chen et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2008)
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4
JP Powers et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis
MH Pourgholami et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
LD Zhang et al.
CANCER GENE THERAPY (2005)
In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
MH Pourgholami et al.
CANCER LETTERS (2001)
分享论文
